Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020)
Xenon Pharmaceuticals (XENE) posted quarterly Short term Debt of $15.7 million for Q1 2020, up 237.12% quarter-over-quarter from $4.6 million in Q4 2019.
Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Short term Debt for 4 consecutive years, with $15.7 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Short term Debt changed N/A year-over-year to $15.7 million; the TTM figure through Mar 2020 stood at $15.7 million (changed N/A YoY), while the FY2019 annual figure was $4.6 million, changed N/A from the prior year.
- Short term Debt climbed to $15.7 million in Q1 2020 per XENE's latest filing, from $4.6 million in the prior quarter.
- Across five years, Short term Debt topped out at $15.7 million in Q1 2020 and bottomed at $700000.0 in Q4 2017.
- Historically, Short term Debt has averaged $4.7 million across 4 years, with a median of $2.8 million in 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 15.68 Mn |
| Dec 31, 2019 | 4.65 Mn |
| Sep 30, 2019 | 3.62 Mn |
| Jun 30, 2019 | 2.07 Mn |
| Mar 31, 2018 | 1.40 Mn |
| Dec 31, 2017 | 700,000.00 |